Twist2 is a valuable prognostic biomarker for colorectal cancer

Table 1 Relationship between Twist2 expression and clinicopathological characteristics n (%)

Characteristics	Total	Twist2 expression		P value
		Negative	Positive
Gender
Female	52 (55.9)	18 (66.7)	34 (51.5)	0.1821
Male	41 (44.1)	9 (33.3)	32 (48.5)
Age
< 59	41 (44.1)	13 (48.1)	28 (42.4)	0.6141
≥ 59	52 (55.9)	14 (51.9)	38 (57.6)
T-stage
T1-2	17 (18.3)	5 (18.5)	12 (18.2)	1.0002
T3-4	76 (81.7)	22 (81.5)	54 (81.8)
N-stage
N0	52 (55.9)	17 (63.0)	35 (53.0)	0.3811
N1-2	41 (44.1)	10 (37.0)	31 (47.0)
M-stage
M0	52 (55.9)	17 (63.0)	35 (53.0)	0.3811
M1	41 (44.1)	10 (37.0)	31 (47.0)
Tumor differentiation
Moderate/good	83 (89.2)	26 (96.3)	57 (86.4)	0.2712
Poor	10 (10.8)	1 (3.7)	9 (13.6)
Vascular invasion
No	56 (60.2)	17 (63.0)	39 (59.1)	0.7291
Yes	37 (39.8)	10 (37.0)	27 (40.9)
Tumor location
Rectum	19 (20.4)	4 (14.8)	15 (22.7)	0.3901
Colon	74 (79.6)	23 (85.2)	51 (77.3)
CEA level (ng/mL)
≤ 5	48 (51.6)	12 (4.4)	36 (54.5)	0.3761
> 5	45 (48.4)	15 (55.6)	30 (45.5)

¹Pearson’s χ² test;

²Fisher’s exact test. T-, N-, M-stage are tumor, node, and metastasis stage (6^th edition), performed according to the American Joint Committee on Cancer; CEA: Serum carcinoembryonic antigen.